Cargando…

Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type 2 diabetes patients: a multicenter real-world study

OBJECTIVES: Semaglutide is a glucagon-like peptide 1 receptor agonist that improves glycemic control and achieves weight loss in type 2 diabetes (T2D) patients. Subcutaneous (s.c.) semaglutide at 1 mg once weekly (OW) is safe in T2D patients with chronic kidney disease (CKD). Whether or not CKD and...

Descripción completa

Detalles Bibliográficos
Autores principales:	García de Lucas, María Dolores, Caballero, Irene, Fernández-García, José Carlos, Domínguez-Rodríguez, Manuel, Moreno-Moreno, Paloma, Jiménez-Millán, Anabel, Botana-López, Manuel, Avilés, Beatriz, Merino-Torres, Juan Francisco, Soto, Alfonso, Tejera, Cristina, Morales, Cristóbal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634592/ https://www.ncbi.nlm.nih.gov/pubmed/37955013 http://dx.doi.org/10.3389/fendo.2023.1240279

Ejemplares similares

Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain
por: Garcia de Lucas, Maria Dolores, et al.
Publicado: (2022)

Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression—real-world clinical practice
por: Aviles Bueno, Beatriz, et al.
Publicado: (2022)

Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)

Effectiveness and safety of dapagliflozin in real-life patients: data from the DAPA-RWE Spanish multicentre study
por: Morales, Cristóbal, et al.
Publicado: (2022)

Corrigendum: Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)

Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice
por: Pérez-Belmonte, Luis M., et al.
Publicado: (2022)

The Discovery and Development of Liraglutide and Semaglutide
por: Knudsen, Lotte Bjerre, et al.
Publicado: (2019)

Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation
por: Meier, Juris J.
Publicado: (2021)

Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide
por: Gallwitz, Baptist, et al.
Publicado: (2021)

Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model
por: Niu, Shu, et al.
Publicado: (2022)

Effects of semaglutide on vascular structure and proteomics in high-fat diet-induced obese mice
por: Yue, Lin, et al.
Publicado: (2022)

A Silent Corticotroph Pituitary Carcinoma: Lessons From an Exceptional Case Report
por: Remón-Ruiz, Pablo, et al.
Publicado: (2021)

Postoperative water and electrolyte disturbances after extended endoscopic endonasal transsphenoidal surgery
por: Canelo Moreno, Juan Manuel, et al.
Publicado: (2022)

Proteomic analysis reveals semaglutide impacts lipogenic protein expression in epididymal adipose tissue of obese mice
por: Zhu, Ruiyi, et al.
Publicado: (2023)

Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6
por: Nauck, Michael A., et al.
Publicado: (2021)

Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials
por: Zhang, Rui, et al.
Publicado: (2023)

Editorial: Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist With Both Injectable and Oral Formulations
por: Meier, Juris J., et al.
Publicado: (2021)

Combination Therapy With Semaglutide and Dapagliflozin as an Effective Approach for the Management of Type A Insulin Resistance Syndrome: A Case Report
por: Martínez-Montoro, José Ignacio, et al.
Publicado: (2022)

Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: A retrospective, cohort study (Sema-MiDiab01)
por: Berra, Cesare C., et al.
Publicado: (2023)

An Update on Semaglutide Research: A Bibliometric Analysis and a Literature Review
por: Dagli, Namrata, et al.
Publicado: (2023)

Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study
por: Volpe, Sara, et al.
Publicado: (2023)

Alpelisib-Induced Diabetes Mellitus: Case Report, Pharmacodynamics and Management Considerations
por: Pla Peris, Begoña, et al.
Publicado: (2022)

Efficacy of Semaglutide in Treating Obesity: A Systematic Review of Randomized Controlled Trials (RCTs)
por: Anam, Mahvish, et al.
Publicado: (2022)

Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis
por: Patel, Tirath, et al.
Publicado: (2023)

Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses
por: Pratley, Richard E, et al.
Publicado: (2020)

Oral Semaglutide
por: Bui, Vinh, et al.
Publicado: (2018)

Identifying advanced MAFLD in a cohort of T2DM and clinical features
por: Sanchez-Bao, Ana Maria, et al.
Publicado: (2023)

Glycemic Control and the Weight Benefit of a Daily 7 mg Dose of Oral Semaglutide Versus an Alternate-Day 14 mg Dose of Oral Semaglutide From an Ambulatory Glucose Monitoring Data: A Retrospective Cohort Study From Eastern India
por: RoyChaudhuri, Soumyabrata, et al.
Publicado: (2023)

Characterization of Genetic Variants of Uncertain Significance for the ALPL Gene in Patients With Adult Hypophosphatasia
por: Sanabria-de la Torre, Raquel, et al.
Publicado: (2022)

Do patients with type 2 diabetes have impaired hip bone microstructure? A study using 3D modeling of hip dual-energy X-ray absorptiometry
por: Ubago-Guisado, Esther, et al.
Publicado: (2023)

Circadian Genes as Therapeutic Targets in Pancreatic Cancer
por: García-Costela, María, et al.
Publicado: (2020)

G Protein-Coupled Estrogen Receptor Immunoreactivity Fluctuates During the Estrous Cycle and Show Sex Differences in the Amygdala and Dorsal Hippocampus
por: Llorente, Ricardo, et al.
Publicado: (2020)

Fibroblast growth factor 21 is expressed and secreted from skeletal muscle following electrical stimulation via extracellular ATP activation of the PI3K/Akt/mTOR signaling pathway
por: Arias-Calderón, Manuel, et al.
Publicado: (2023)

Indocyanine green angiography-guided thyroidectomy versus conventional thyroidectomy for preserving parathyroid function: study protocol for a randomized single-blind controlled trial
por: Moreno-Llorente, Pablo, et al.
Publicado: (2023)

An elevated parametric thyroid feedback quantile-based index is associated with atrial fibrillation
por: Alonso-Ventura, Vanesa, et al.
Publicado: (2023)

Switch-to-Semaglutide Study (STS-Study): a Retrospective Cohort Study
por: Hepprich, Matthias, et al.
Publicado: (2021)

Semaglutide for type 2 diabetes
Publicado: (2020)

Semaglutide-associated bullous pemphigoid
por: Burruss, Clayton P., et al.
Publicado: (2021)

Semaglutide-eye-catching results
por: Cigrovski Berkovic, Maja, et al.
Publicado: (2023)

Emerging Anesthesia Risks with Semaglutide
por: Fezza, Reed, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_baeg80uijrt4q9rhiqctd74kgf